Pharma

Boehringer Ingelheim Pharmaceuticals has introduced Striverdi Respimat (olodaterol) inhalation spray 5µg in the US market.

Striverdi Respimat is indicated to treat airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

The company noted that Striverdi Respimat is now available by prescription in pharmacies across the country.

"Approximately 15 million Americans have been told by a healthcare provider that they have COPD."

Boehringer Ingelheim Pharmaceuticals marketing senior vice-president Kathleen Dowd said: "For over a half century, Boehringer Ingelheim has been a leader in discovering and developing new therapies for respiratory diseases.

"We’re proud to build upon our respiratory heritage by bringing Striverdi Respimat to market as a new COPD maintenance treatment option."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Approximately 15 million Americans have been told by a healthcare provider that they have COPD, and we believe Striverdi Respimat will be a welcome option for providers and patients alike."

US Food and Drug Administration (FDA) granted approval for olodaterol in July, which is a long-acting beta agonist (LABA) that can be delivered through the Respimat inhaler.

The approval was based on data from eight Phase III clinical trials, which involved 4,450 patients with COPD.

COPD is a term including chronic bronchitis and emphysema, and the most common symptom of it is shortness of breath. The disease results in harder breathing, as less air is able to flow in and out of the lungs.


Image: Low-magnification micrograph of emphysema. H&E stain. Photo: courtesy of Nephron.